Business
ENDRA Life Sciences Granted Additional European Patent As Commercialization Begins
New grant expands coverage of key U.S. platform patent to EuropeANN ARBOR, MI / ACCESSWIRE / July 22, 2020 / ENDRA Life Sciences Inc. (''ENDRA'')
About this update from Endra Life Sciences Inc.
[{"type":"text","content":"New grant expands coverage of key U.S. platform patent to EuropeANN ARBOR, MI / ACCESSWIRE / July 22, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued European Patent 3328285 from the European Patent Office (EPO).\"The granting of our second European patent comes at an opportune time, as we're currently focusing on finalizing our first clinical evaluation reference sites in Europe and initiating sales in this key market, where the TAEUS Fatty Liver Imaging Probe System received CE Mark Approval in the first half of the year,\" said ENDRA's Chief Executive Officer, Francois Michelon.The recently issued patent extends coverage to Europe for an important platform capability of TAEUS covered in the related U.S. patent, US10022107. More specifically, the patent covers ENDRA's method and system to improve ultrasound image quality and spatial resolution in tissue regions where fat-induced artifacts impair conventional ultrasound reconstruction methods. ENDRA's method and system also potentially reduces the computation-time that is typically required to correct for fat-related aberrations.Kai Thomenius PhD, a research scientist at the Institute of Medical Engineering & Science at The Massachusetts Institute of Technology (MIT) and co-inventor of the patent, said, \"This is a novel approach to correcting fat induced image distortion in ultrasound imaging, leveraging the inherent fat and lean tissue contrast of thermoacoustics.\"\"While our European patent grants are significant because they apply to our platform capabilities in our first commercial market, it is important to understand these patents are supported and strengthened by the fact they are part of a growing IP portfolio, which currently stands at 72 assets, which cover other critical aspects of our technology,\" concluded Michelon.About ENDRA Life Sciences Inc.ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like an MRI, but at 1/50th of the cost, at the point of patient care. TAEUS is designed to work in concert with existing ultrasound systems. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) ...